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Abstract
Adenosine, through activation of its A1 receptors, has neuroprotective effects during hypoxia and ischemia. Recently, using
transgenic mice with neuronal expression of human equilibrative nucleoside transporter 1 (hENT1), we reported that
nucleoside transporter-mediated release of adenosine from neurons was not a key mechanism facilitating the actions of
adenosine at A1 receptors during hypoxia/ischemia. The present study was performed to test the importance of CD73 (ecto-
59-nucleotidase) for basal and hypoxic/ischemic adenosine production. Hippocampal slice electrophysiology was performed
with CD73
+/+ and CD73
2/2 mice. Adenosine and ATP had similar inhibitory effects in both genotypes, with IC50 values of
approximately 25 mM. In contrast, ATP was a less potent inhibitor (IC50=100 mM) in slices from mice expressing hENT1 in
neurons. The inhibitory effects of ATP in CD73
+/+ and CD73
2/2 slices were blocked by the adenosine A1 receptor antagonist
8-cyclopentyl-1,3-dipropylxanthine (DPCPX) and were enhanced by the nucleoside transport inhibitor S-(4-nitrobenzyl)-6-
thioinosine (NBTI), consistent with effects that are mediated by adenosine after metabolism of ATP. AMP showed a similar
inhibitory effect to ATP and adenosine, indicating that the response to ATP was not mediated by P2 receptors. In comparing
CD73
2/2 and CD73
+/+ slices, hypoxia and oxygen-glucose deprivation produced similar depression of synaptic transmission
in both genotypes. An inhibitor of tissue non-specific alkaline phosphatase (TNAP) was found to attenuate the inhibitory
effects of AMP and ATP, increase basal synaptic activity and reduce responses to oxygen-glucose deprivation selectively in
slices from CD73
2/2 mice. These results do not support an important role for CD73 in the formation of adenosine in the CA1
area of the hippocampus during basal, hypoxic or ischemic conditions, but instead point to TNAP as a potential source of
extracellular adenosine when CD73 is absent.
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Introduction
ATP and adenosine inhibit synaptic transmission in electrically
stimulated hippocampal slices [1]. The inhibitory effect of
adenosine is mediated by adenosine A1 receptors, as determined
through the use of selective antagonists and A1 receptor knockout
(
2/2) mice [1]. ATP appears to also act through A1 receptors as its
inhibitory effects are blocked by A1 selective antagonists, but not
by purinergic P2 receptor antagonists [2]. Furthermore, the
inhibitory effects of ATP are not observed in A1 receptor
2/2 mice
[1]. Since ATP does not activate A1 receptors directly, this
indicates that ATP is rapidly metabolized to adenosine and its
inhibitory effects are actually mediated by adenosine [3].
Extracellular ATP can be metabolized to adenosine by a
combination of enzymes. Ecto-nucleoside triphosphate dipho-
sphohydrolases (E-NTPDases; ecto-apyrases; CD39), ecto-nucleo-
tide pyrophosphatase/phosphodiesterases (E-NPPs) and alkaline
phosphatases metabolize ATP and ADP to AMP, whereas alkaline
phosphatases and CD73 (ecto-59-nucleotidase; EC 3.1.3.5) can
metabolize AMP to adenosine [4]. However, inhibitors of these
enzymes have modest efficacy to decrease the effects of ATP or
AMP and can have inhibitory effects of their own [3,5–7]. It has
been difficult to demonstrate conclusively that the inhibitory
effects of exogenous adenine nucleotides result from their
metabolism extracellularly to adenosine, in part, because their
slow metabolism of variable efficacy is in contrast to their rapid
inhibition of synaptic activity [2,7].
Recently, we developed transgenic (Tg) mice that express
human equilibrative nucleoside transporter 1 (hENT1) under the
control of a neuron-specific promoter [8]. Radioligand binding
assays showed a 20-fold increase in ENT1 abundance in Tg
hippocampal membranes, relative to membranes from wild type
(Wt) mice [9]. Using hippocampal slice electrophysiology, we
reported that the potency of applied adenosine was decreased in
slices from hENT1 Tg mice, indicating that increased cellular
uptake of adenosine led to decreased adenosine A1 receptor
activation [9]. Furthermore, both hypoxic and oxygen-glucose
deprivation conditions produced less inhibition of synaptic activity
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5in slices from hENT1 Tg mice, relative to slices from Wt littermate
controls [9]. From this, we concluded that hypoxic/ischemic
conditions do not trigger equilibrative transporter-mediated
release of adenosine per se from neurons, despite rapid decreases
in neuronal ATP levels. Instead, we proposed that adenosine is
released from another cell type or via another mechanism, or ATP
(or another nucleotide) is released and metabolized extracellularly
to adenosine during hypoxic/ischemic conditions [9].
To address these potential mechanisms, the present study was
performed. As CD73 is a key enzyme for the extracellular
formation of adenosine [4], we used CD73
+/+ and CD73
2/2 mice
to test whether CD73 deficiency affects responses to adenosine,
ATP, hypoxia or oxygen-glucose deprivation in hippocampal slice
preparations. Previous studies have reported that both adenosine
formation and adenosine receptor activity were reduced in
CD73
2/2 mice [10–13]. In addition, tissue-nonspecific alkaline
phosphatase (TNAP) has been shown to metabolize extracellular
ATP in cultured hippocampal neurons and regulate axonal growth
[14]. Therefore, we also tested whether TNAP affects responses to
ATP, AMP, hypoxia or oxygen-glucose deprivation through the
use of the inhibitor 2,5-dimethoxy-N-(quinolin-3-yl)benzenesulfo-
namide (TNAP-I) [15].
Materials and Methods
Ethics statement
All procedures with animals were in accordance with guidelines
set by the Canadian Council on Animal Care and approved by the
University of Manitoba Animal Protocol Management and
Review Committee.
Mice
CD73
2/2 mice were obtained from Dr. Linda Thompson [13].
Male CD73
2/2 and wild type (CD73
+/+) C57Bl6 mice were used
at 8 weeks of age. In some experiments male mice expressing
hENT1 under the control of neuron specific enolase promoter,
and wild type littermates, were used at 8 weeks of age [8].
PCR and reverse transcriptase PCR for CD73
Genomic DNA was extracted from tail snips using the WizardH
Genomic DNA Purification Kit (Promega Corporation), following
the manufacturer’s protocol. RNA was isolated from cortex or
hippocampus samples using the TRIzol
TM method (Invitrogen).
The concentration of RNA was measured using a GeneQuant Pro
spectrophotometer (Biochrom, Ltd.) and diluted to 1.5 mg/mL
using ddH2O. Reverse transcription (RT) was performed by first
treating 1.5 mg RNA with 1 U DNase (Invitrogen) in 20 mM Tris-
HCl (pH 8.4), 2 mM MgCl2 and 50 mM KCl at room temper-
ature for 15 min. Then, 500 ng olig(dT)12–18 primer and was
added and heated to 65uC for 5 min. The final step consisted of
the addition of Moloney-murine leukemia virus reverse transcrip-
tase (200 U), dNTPs (0.5 mM), dithiothreitol (DTT; 10 mM),
Tris-HCl (50 mM; pH 8.3), KCl (75 mM) and MgCl2 (3 mM) in a
final volume of 60 mL, then incubated at 37uC for 1 h followed by
90uC for 5 min.
Figure 1. Loss of ecto-59-nucleotidase activity in CD73
2/2 mice.
(a) Genomic DNA was isolated from three CD73
2/2 (1, 2, 3) and three
CD73
+/+ (4, 5, 6) mice. Multiplex PCR was performed using primer set 1,
to amplify exon 10–11, or primer set 2, to amplify from the region of
mutated DNA, together with primers to mouse beta casein. While PCR
amplified the beta casein internal control gene and the 39end of CD73
in all samples, only samples from CD73
2/2 mice produced a PCR
product from the mutated region of the CD73 gene. (b) Total RNA was
isolated from cerebral cortex from three CD73
2/2 (1, 2, 3) and three
CD73
+/+ (4, 5, 6) mice. RNA was reverse transcribed and cDNA for CD73
exons 3–4 was amplified using primer set 3. A PCR product of the
expected size was obtained with cDNA from CD73
+/+ but not CD73
2/2
mice. (c) Membrane preparations from cerebral cortex from CD73
+/+
and CD73
2/2 mice were incubated with
14C-AMP (100 mM) and
metabolism to adenosine, inosine and hypoxanthine was measured.
AOPCP (50 mM) was added to some samples to inhibit CD73 (ecto-59-
nucleotidase) activity. Data are pmol/mg protein expressed as a
percentage of total
14C-AMP applied, from 3 assays performed in
triplicate. ***p,0.001, one way ANOVA with Tukey’s post-hoc tests. (d)
Hippocampal slices from CD73
+/+ and CD73
2/2 mice were incubated
with
14C-AMP (100 mM) and metabolism to adenosine, inosine and
hypoxanthine was measured before (0–15 min) or during (15–45 min)
electrical stimulation. Data are disintegrations per min from 2 CD73
+/+
or 4 CD73
2/2 slices (1 slice per animal). *p,0.05, **p,0.01, ***p,0.001,
two-tailed t-tests.
doi:10.1371/journal.pone.0039772.g001
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was 59-GTGACCCTCCCAAGCTATCTG and 59-
GCTTCCCTGGTAATGACTTGC; these primers span exons
10 and 11 of CD73 and are predicted to amplify a sequence of
1.1 kb. Primer set 2 was 59-AAGGAGGGGTGCATCTTGC-
TATTC and 59-CCAGCTCATTCCTCCCACTCATG; these
primers target intron 2 and the mutated sequence in exon 3 [13]
and are predicted to amplify a sequence of 1 kb only in CD73
2/2
mice. Primer set 3 was 59-TCAGAAAGTTCGAGGTGTGGA
and 59-GTCCATCATCTGCGGTGACTA; these primers span
exons 3 and 4 of CD73 and are predicted to amplify a sequence of
128 bp in wild type cDNA from cerebral cortex. Multiplex PCR
was performed using CD73 and mouse beta casein gene specific
primers, as described previously [8]. Ready To Go
TM PCR beads
(GE Healthcare) and 500 nM of primer mix (forward and reverse)
were used to amplify 1 mL of DNA or cDNA. A PTC-100
TM
Programmable Thermal Controller (MJ Research, Inc.) was used
for the amplification. The ‘slowdown PCR’ program [16] was used
with cDNA because it had been found previously to reduce
primer-dimers and give cleaner results.
A 1% agarose gel, containing ethidium bromide for visualiza-
tion, was run in Tris acetate-EDTA (TAE) buffer (40 mM Tris
acetate and 1 mM EDTA) for 30 290 min at 105 V and the PCR
products were cut from the gel while being illuminated by a FBTI-
88 Transilluminator (Fisher Scientific).
Quantitative PCR for TNAP
For quantitative PCR reaction mixtures, with a final volume of
50 ml, consisted of 1 ml reverse transcribed cDNA, 0.5 mM
primers, 2.5 mM MgCl2, 0.2 mM dNTPs, 0.16 SYBR Green I,
0.25 U Platinum Taq polymerase and10 nM fluorescent calibra-
tion dye. The reactions consisted of 4 min at 95uC then 50 cycles
of 95uC for 15 sec, 64uC for 15 sec, 72uC for 30 sec. This was
immediately followed by a melt curve analysis consisting of 95uC
for 1 min, 64uC for 1 min and 64uC for 10 sec, with the latter step
increasing in temperature by 0.5uC per cycle for 63 cycles. Melt
curve analysis confirmed the presence of a single PCR product in
each reaction. A Bio-Rad iCycler iQ Real-Time PCR Detection
System was used for these experiments.
Primer sequences for b-actin were 59-
CATGGCTGGGGTGTTGAAGGTTCT and 59- CGAGCCC-
CAGAGCAAGAGAGGT and for TNAP were 59- ACGGA-
CATCATGAGGGTAAGG and 59- CGTGGGAATGATCAG-
CAGTAA. Expected product sizes were 188 bp and 132 bp for b-
actin and TNAP, respectively. For both primer pairs, standard
curves were linear over a range of 5–6 log units and reaction
efficiencies were between 90–110%.
Ecto-59-nucleotidase assays
Cell membranes were isolated from cortex obtained from
CD73
+/+ and CD73
2/2 mice using previously published methods
[8]. Briefly, cortex from each mouse was homogenized in 10
volumes of ice-cold 0.32 M sucrose then centrifuged at 10006 g
for 10 min at 4uC. The pellet was washed twice and pooled
supernatants were centrifuged at 20,0006 g for 30 min at 4uC.
The resulting pellets were resuspended in HEPES buffer
composed of 110 mM NaCl, 25 mM glucose, 68.3 mM sucrose,
5.3 mM KCl, 1.8 mM CaCl2, 1.0 mM MgSO4 and 20 mM
HEPES, pH 7.4. Protein concentrations were determined with a
Bio-Rad dye binding assay.
Ecto-59-nucleotidase assays were performed in triplicate in an
assay volume of 0.3 ml with 100 mM
14C-AMP and 40 mg
membrane protein per assay for 15 min at room temperature.
a,b-methylene ADP (AOPCP; 50 mM) was used to inhibit ecto-59-
nucleotidase and TNAP-I was used to inhibit TNAP (10 mM).
Assays were terminated by centrifugation (14,0006g; 2 min).
14C-
purines (AMP, adenosine, inosine and hypoxanthine) were
separated by thin layer chromatography, using n-butanol, ethyl
acetate, methanol and ammonium hydroxide in a ratio of 7:4:3:4
vol/vol, then quantified by scintillation spectroscopy [17,18]. The
amount of adenosine, inosine and hypoxanthine produced was
expressed as a percentage of the AMP added.
Ecto-59-nucleotidase assays were also performed with hippo-
campal slices, prepared as described below. Hippocampal slices
were kept at 32.5uC with 1 ml of artificial cerebrospinal fluid
(aCSF) containing 10 mM[
14C]AMP. Samples (50 ml) were taken
at 5 min intervals for 45 min and analyzed for [
14C]adenosine
Figure 2. Inhibition by adenosine of fEPSP recordings in
hippocampal slices from CD73
+/+ and CD73
2/2 mice. (a)
Representative traces of fEPSPs; numbers 1–6 correspond to before
and during superfusion of slices with adenosine (10, 25, 50 or 100 mM)
or adenosine (100 mM) and DPCPX (1 mM) as indicated in (b). (b) The
effect of adenosine on fEPSP slope in hippocampal slices from CD73
+/+
and CD73
2/2 mice. Horizontal lines represent the duration of
superfusion with the indicated adenosine concentrations. (c) Maximum
inhibition of fEPSPs obtained with each concentration of adenosine.
n=3 CD73
+/+ and 3 CD73
2/2.
doi:10.1371/journal.pone.0039772.g002
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collections, slices were electrically stimulated as described below
for the remaining 30 min.
Hippocampal slice preparation
Mice were anaesthetized with isoflurane and decapitated. Each
brain was rapidly removed in ice-cold oxygenated (95% O2/5%
CO2) aCSF of the following composition (mM): 124 NaCl, 3.0
KCl, 1.2 MgCl2, 2.0 CaCl2, 1.25 KH2PO4, 26 NaHCO3,1 0D -
glucose, pH 7.4, adjusted to 285–290 mOsm. Hippocampus was
removed and 350 mm slices were cut using a McIlwain tissue
chopper (Stoelting Co, Wood Dale, IL). The slices were then
allowed to recover in a holding chamber for at least 1 hr at 32.5uC
prior to electrophysiological recording or ecto-59-nucleotidase
assays.
Extracellular recording
Individual slices were transferred to a submerged recording
chamber (Harvard Apparatus, Holliston, MA) and continuously
superfused with oxygenated aCSF at a flow rate of 1.5 ml/min
(32.5uC). Each slice was placed on a suspended nylon net to allow
perfusion and oxygenation of the slice from above and below.
Synaptic responses were evoked by stimulation of the Schaffer
collateral/commissural pathway with a concentric bipolar stimu-
lating electrode with 0.1 millisecond pulse width at 30 second
intervals. Extracellular field excitatory postsynaptic potentials
(fEPSPs) were recorded in stratum radiatum of CA1 hippocampus
using glass microelectrodes (1–2 V) filled with aCSF. Input/output
curves were obtained by gradual increases in stimulus voltage at
the beginning of each experiment, when a stable baseline of fEPSP
response was reached. The baseline recording was established at
40–50% maximal fEPSP response. At least 15 to 20 min of stable
baseline was obtained in each experiment. Data were collected
using an Axopatch 1D amplifier and analyzed using pCLAMP 10
software (Molecular Devices, Sunnyvale, CA).
Application of hypoxia or oxygen-glucose deprivation
In vitro hypoxia, 10 min, was induced by superfusing slices with
aCSF gassed with 95% N2/5% CO2. In vitro oxygen-glucose
deprivation, 3 min, was induced by superfusing slices with aCSF
prepared with sucrose instead of glucose and gassed with 95% N2/
5% CO2.
Drugs
ATP, adenosine, AOPCP, S-(4-nitrobenzyl)-6-thioinosine
(NBTI), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), dimethyl-
sulfoxide (DMSO) were purchased from Sigma-Aldrich Canada
Ltd (Oakville ON). TNAP-I was purchased from Calbiochem
(Mississauga, ON). Adenosine and ATP were prepared in distilled
water then diluted to 10–100 mM in aCSF. A spectrophotometer
was used to ensure the accuracy of final concentrations using the
extinction coefficients at l 259 of 15.1 mm
21?cm
21 and
15.4 mm
21?cm
21 for adenosine and ATP, respectively. NBTI,
DPCPX and TNAP-I were dissolved in DMSO, then diluted in
aCSF to obtain DMSO concentrations of 0.01% (NBTI, DPCPX)
or 0.1% (TNAP-I).
Statistical analysis
All numerical data are expressed as means 6 SEM. Data were
tested for statistical significance with two-tailed Student’s t-test or
one way ANOVA with Tukey’s post hoc tests. A value of p,0.05
was considered statistically significant.
Results
Characterization of CD73
2/2 mouse model
PCR, reverse transcriptase PCR and ecto-59-nucleotidase assays
were performed to verify the absence of CD73 in CD73
2/2 mice
and its presence in CD73
+/+ mouse samples. Primer set 1, which
targets exons 10 and 11, amplified a 1.1 kb sequence from
genomic DNA of both CD73
+/+ and CD73
2/2 mice (Fig. 1A).
Primer set 2, which targets the region of the gene that was mutated
to produce the knock out phenotype, amplified a 1 kb sequence
from genomic DNA isolated from CD73
2/2 mice. As expected
these primers did not produce a PCR product using CD73
+/+
DNA (Fig. 1A). Primer set 3, which targets exon 3–4, the region
disrupted in the genome of the CD73
2/2 mice, amplified a
128 bp sequence of cDNA from CD73
+/+ but not CD73
2/2
cortex (Fig. 1B) and hippocampus (data not shown). Thus, the
PCR and reverse transcriptase PCR results confirm that the CD73
gene and its expression are disrupted in CD73
2/2 mice.
Ecto-59-nucleotidase assays were performed with cell mem-
branes isolated from cerebral cortex. Approximately 2164%
(22167.5 pmol/mg protein) of the
14C-AMP was hydrolyzed to
adenosine in assays using samples from CD73
+/+ mice. AOPCP
(50 mM) significantly inhibited adenosine formation, with 561%
(6261.3 pmol/mg protein) of the AMP metabolized to adenosine.
In contrast, in parallel assays using samples from CD73
2/2 mice,
less than 3% (2461.3 pmol/mg protein) of AMP was metabolized
to adenosine and AOPCP had no effect (2660.5 pmol/mg protein)
(Fig. 1C). Inosine and hypoxanthine were also quantified, but their
levels were less than 3% of AMP both with CD73
2/2 and CD73
+/
+ samples and were unaffected by AOPCP.
Conversion of [
14C]AMP to [
14C]adenosine was also examined
in hippocampal slices. Significantly greater quantities of
[
14C]adenosine were detected in superfusate of CD73
+/+ slices,
relative to CD73
2/2 slices (Fig. 1D), both before (0–15 min) and
during (15–45 min) electrical stimulation.
Hippocampal slices from CD73
+/+ and CD73
2/2 mice
show similar responses to adenosine and ATP
Adenosine produced a concentration dependent decrease in
synaptic activity, with an IC50 value of approximately 25 mM and
almost complete inhibition was observed with 100 mM adenosine
(Fig. 2A–B). This inhibitory effect of adenosine was mediated by
adenosine A1 receptors, since the A1 selective antagonist DPCPX
restored synaptic activity to control levels (Fig. 2A). As expected,
no significant differences in the effects of adenosine were observed
between hippocampal slices obtained from CD73
+/+ or CD73
2/2
mice.
The absence of ecto-59-nucleotidase activity is predicted to
reduce or abolish the effects of ATP that are sensitive to inhibition
by DPCPX. However, ATP produced a concentration dependent
decrease in synaptic activity in both CD73
+/+ or CD73
2/2
hippocampal slices (Fig. 3A). The IC50 value for ATP was
approximately 25 mM, and 100 mM produced almost complete
cessation of synaptic activity (Fig. 3B). As with adenosine, DPCPX
blocked the effects of ATP. While the overall effects of ATP were
very similar to adenosine, one noticeable difference was that there
was a slower response to each individual concentration of ATP
(compare Fig. 2A, 3A), indicating that responses to ATP were
slower to equilibrate. There was a trend for a greater inhibitory
effect of ATP in CD73
2/2 slices compared to CD73
+/+ slices,
which was statistically significant (p,0.05) at 25 mM ATP.
Regulation of Adenosine Levels in CD73
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show reduced responses to ATP
Previously, we reported that exogenous adenosine was a more
potent inhibitor of synaptic activity in wild type, compared to
hENT1 transgenic, hippocampal slices [9]. To test whether
enhanced neuronal uptake of adenosine affects hippocampal
responses to ATP, we used slices from hENT1 transgenic and wild
type littermates. Similar to results with adenosine in hENT1
transgenic mice, but in contrast to results with CD73
+/+ and
CD73
2/2 slices, ATP had significantly reduced potency for
inhibiting synaptic activity in hENT1 transgenic slices, relative to
wild type slices (Fig. 4).
Basal adenosine levels are similar in hippocampal slices
from CD73
+/+ and CD73
2/2 mice
DPCPX tended to increase synaptic activity in hippocampal
slices from both CD73
+/+ and CD73
2/2 mice (Fig. 5A), although
a high degree of variability between samples was evident. After
10 min treatment with DPCPX, fEPSP slope values were
11469% and 11568% in CD73
+/+ and CD73
2/2, respectively.
DPCPX prevented the inhibitory effects of ATP (Fig. 5A); after
5 min treatment with ATP in the continued presence of DPCPX,
fEPSP slope remained at 116612% and 11367% in CD73
+/+
and CD73
2/2, respectively.
NBTI, a selective inhibitor of ENT1, produced a slowly
developing inhibition of synaptic activity (Fig. 5B). After 20 min
treatment with NBTI, fEPSP slope was decreased to 8961% in
both CD73
+/+ and CD73
2/2 slices. In the presence of NBTI,
treatment for 10 min with ATP produced a further decrease in
Figure 3. Inhibition by ATP of fEPSP recordings in hippocampal
slices from CD73
+/+ and CD73
2/2 mice. (a) Representative traces of
fEPSPs; numbers 1–6 correspond to before and during superfusion of
slices with ATP (10, 25, 50 or 100 mM) or ATP (100 mM) and DPCPX
(1 mM) as indicated in (b). (b) The effect of ATP on fEPSP slope in
hippocampal slices from CD73
+/+ and CD73
2/2 mice. Horizontal lines
represent the duration of superfusion with the indicated ATP
concentrations. (c) Maximum inhibition of fEPSPs obtained with each
concentration of ATP. n=4 CD73
+/+ and 5 CD73
2/2.
doi:10.1371/journal.pone.0039772.g003
Figure 4. Inhibition by ATP of fEPSP recordings in hippocampal
slices from hENT1 Tg and Wt mice. (a) Representative traces of
fEPSPs; numbers 1–6 correspond to before and during superfusion of
slices with ATP (10, 25, 50 or 100 mM) or ATP (100 mM) and DPCPX
(1 mM) as indicated in (b). (b) The effect of ATP on fEPSP slope in
hippocampal slices from hENT1 Tg and Wt littermate mice. Horizontal
lines represent the duration of superfusion with the indicated ATP
concentrations. (c) Maximum inhibition of fEPSPs obtained with each
concentration of ATP. n=4 hENT1 Tg and 4 Wt.
doi:10.1371/journal.pone.0039772.g004
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+/+ and
CD73
2/2, respectively.
AOPCP, an inhibitor of ecto-59-nucleotidase, had no effect on
synaptic activity in slices from CD73
+/+ and CD73
2/2 (Fig. 5C).
In the presence of AOPCP, treatment for 10 min with ATP
(10 mM), produced a decrease in fEPSP values to 6964% and
6863% in CD73
+/+ and CD73
2/2, respectively. Field EPSP
values returned to 10161 and 9861% in CD73
+/+ and CD73
2/
2, respectively, upon washout of ATP but recovery was
significantly slower in CD73
2/2 slices (p,0.05).
Hippocampal slices from CD73
+/+ and CD73
2/2 mice
show similar responses to hypoxia and to oxygen-
glucose deprivation
Previous studies have demonstrated hypoxia produces synaptic
inhibition that is caused, in part, by adenosine acting at A1
receptors [19,20]. Our previous study showed that this adenosine
is not released via equilibrative transporters from neurons [9], but
the study did not examine whether it was due to metabolism of
extracellular ATP to adenosine. Using hippocampal slices from
CD73
+/+ and CD73
2/2 mice, hypoxia (10 min) produced a
complete inhibition of synaptic activity in both (Fig. 6A). There
was a trend towards a slower recovery with CD73
2/2 slices, but
this was not statistically significant. The recovery of synaptic
activity after reoxygenation was similar, reaching 9362% and
9365% in CD73
+/+ and CD73
2/2 slices, respectively.
Hippocampal slices from CD73
+/+ and CD73
2/2 mice were
also exposed to oxygen-glucose deprivation (3 min); a pronounced
decrease in synaptic activity was observed and no differences
between CD73
+/+ and CD73
2/2 in inhibitory response or
recovery were detected (Fig. 6B).
Figure 5. DPCPX and NBTI, but not AOPCP, affect inhibition of
fEPSPs by ATP. Hippocampal slices from CD73
+/+ and CD73
2/2 mice
were superfused with (a) 1 mM DPCPX, (b) 100 nM NBTI or (c) 50 mM
AOPCP as indicated by the horizontal lines. After 10 min (a, c) or 20 (b)
min, 100 mM ATP was applied as indicated by second horizontal line.
n=3–4 CD73
+/+ and 3–4 CD73
2/2.* p,0.05; two tailed t-test.
doi:10.1371/journal.pone.0039772.g005
Figure 6. Effect of hypoxia or oxygen-glucose deprivation
(OGD) on fEPSP recordings. (a) Slices were superfused with hypoxic
aCSF for 10 min as indicated by the horizontal bar. n=7 CD73
+/+ or 9
CD73
2/2 mice. (b) Slices were superfused with hypoxic glucose-free
aCSF for 3 min as indicated by the horizontal bar. n=5 CD73
+/+ or 4
CD73
2/2 mice. There were no significant differences between
genotypes.
doi:10.1371/journal.pone.0039772.g006
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2/2
but not CD73
+/+ mice and contributes to adenosine
production during oxygen-glucose deprivation
Similar to adenosine and ATP, AMP (10 mM) inhibited synaptic
transmission in hippocampal slices from both CD73
+/+ and
CD73
2/2 mice; after 10 min, fEPSP values were 7862 and
7361, respectively (Fig. 7A). For CD73
2/2, but not CD73
+/+,
slices, this inhibition was attenuated by the application of TNAP-I
(10 mM); after 10 min, fEPSP values were 9761 and 6863,
respectively (Fig. 7A). TNAP-I produced a significant increase in
fEPSPs in CD73
2/2 hippocampal slices, consistent with a
decrease in basal adenosine production; after 10 min fEPSPs
were 11362 and 9961 for CD73
2/2 and CD73
+/+, respectively
(p,0.05). Selectively in CD73
2/2 slices, pre-treatment with
TNAP-I abolished the inhibitory effects of 10 mM ATP (Fig. 7B).
Nucleotidase assays were performed to test the effect of TNAP-
I. As shown in Fig. 7C, no effect of TNAP-I was observed in
CD73
+/+ cortical membranes, but a significant inhibition of
adenosine production, from 360.2 to 0.760.1 pmol/mg protein,
was observed in CD73
2/2 samples.
To test the contribution of TNAP to inhibition of fEPSPs by
hypoxia or oxygen-glucose deprivation, slices were superfused with
TNAP-I prior to, during and following hypoxia (10 min) or
oxygen-glucose deprivation (3 min) (Fig. 8A–B). In slices from
CD73
2/2 mice, TNAP-I produced an increase in basal synaptic
transmission and decreased synaptic inhibition produced by
transient oxygen-glucose deprivation (Fig. 8B) but not hypoxia
(Fig. 8A).
TNAP expression is unchanged in CD73 2/2 mice
Since TNAP-I selectively enhanced synaptic transmission in
slices from CD73
2/2 and not CD73
+/+ mice, RT-PCR and
quantitative PCR were performed to examine for a genotype
difference in expression of TNAP. RT-PCR indicated that TNAP
was similarly expressed in hippocampus from CD73
+/+ and
CD73
2/2 mice (data not shown). PCR data from CD73
+/+ and
CD73
2/2 cortex cDNA were normalized to their respective b-
actin values and expressed relative to CD73
+/+ TNAP gene
expression using the 2
2DDCT method [21]. No significant
difference in TNAP expression was detected: means and 95%
confidence intervals were 1.00 (0.70–1.42) and 0.76 (0.52–1.13) for
CD73
+/+ and CD73
2/2, respectively.
Discussion
For the present study, we used CD73
2/2 mice and tested the
hypothesis that CD73 is required for basal and hypoxic/ischemic
adenosine production in the CA1 region of the hippocampus. The
main findings were that (1) CD73 metabolizes AMP to adenosine
in cortical membranes and hippocampal slices; (2) CD73 is not
required for the inhibitory effects of ATP in hippocampal slices;
and (3) CD73 is not required for the inhibitory effects of adenosine
observed in hypoxia or OGD. These data indicate the presence of
another enzyme involved in the metabolism of extracellular ATP
to adenosine. We show that TNAP-I inhibits responses to ATP
and AMP selectively in CD73
2/2 hippocampal slices but it has
only a modest effect to attenuate synaptic inhibition in OGD.
Therefore, the effects of exogenous ATP and endogenous
adenosine are largely independent of both CD73 and TNAP in
wild type mice.
We recently reported that transgenic mice expressing bidir-
ectionalhENT1 in neurons showed decreased adenosine A1
receptor-mediated effects during basal conditions as well as during
hypoxia and oxygen-glucose deprivation [9]. From these data we
concluded that neuronal ENTs were more important for
adenosine uptake than release and suggested that ATP released
as a gliotransmitter from astrocytes may be an important source of
adenosine during basal conditions as well as during conditions of
hypoxia and oxygen-glucose deprivation. To follow up on these
findings, we performed the experiments described here, with
Figure 7. Inhibition of fEPSPs by AMP or ATP is reduced by
TNAP-I selectively in CD73
2/2 slices. (a) Hippocampal slices from
CD73
+/+ and CD73
2/2 mice were superfused with 10 mM AMP as
indicated by the horizontal bar. After 15 min recovery, slices were
superfused with 10 mM AMP plus 10 mM TNAP-I as indicated by the
second horizontal bar. n=3 CD73
+/+ and 3 CD73
2/2. Significant
differences between genotypes are indicated by dashed lines;
p,0.05; unpaired t-tests. (b) Hippocampal slices from CD73
+/+ and
CD73
2/2 mice were superfused with 10 mM TNAP-I and, after 10 min,
with 10 mM ATP as indicated by the horizontal bars. n=3 CD73
+/+ and 3
CD73
2/2. Significant differences between genotypes are indicated by
dashed lines; p,0.05; unpaired t-tests. (c) Inhibition of metabolism of
[
14C]AMP to [
14C]adenosine, [
14C]inosine and [
14C]hypoxanthine by
TNAP-I was determined using membrane preparations from cerebral
cortices. n=4 CD73
+/+ and 4 CD73
2/2.* p,0.05, relative to absence of
TNAP-I; unpaired t-test. Ado, adenosine; Ino, inosine; HX, hypoxanthine.
doi:10.1371/journal.pone.0039772.g007
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2/2 mice. Our results do not provide support for an
important role of CD73 in metabolizing extracellular ATP to
adenosine during basal or hypoxic/ischemic conditions, but do
point to TNAP as a potential source of extracellular adenosine
when CD73 is absent.
Our electrophysiology data could suggest that ecto-59-nucleo-
tidase activity was still present in CD73
2/2 mice. We confirmed
the absence of CD73 using both PCR and reverse transcriptase
PCR. In addition, we performed nucleotidase assays and found
that CD73
+/+ mouse brain samples clearly exhibited this activity,
and at least 90% of this activity was lost in samples from CD73
2/2
mice. Furthermore, AOPCP inhibited adenosine production from
AMP only in samples from CD73
+/+ mice. Metabolism of
[
14C]AMP to adenosine was also examined using hippocampal
slices and electrical stimulation was applied to reproduce the
conditions of slice electrophysiology. [
14C]Adenosine was pro-
duced by slices from CD73
+/+ mice but was very low in slices from
CD73
2/2 mice. Thus, CD73 is an important enzyme that
produces adenosine from exogenously applied AMP, both in
hippocampal slices and brain membrane preparations; however, it
is possible that another enzyme is important in the membrane
microdomains that contain A1 receptors.
The importance of CD73 for synaptic inhibition produced with
ATP was examined. Although we hypothesized that the inhibitory
effects of ATP, on synaptic transmission in hippocampal slices,
would be abolished or significantly attenuated in slices from
CD73
2/2 mice, this was not the case. Not only was the potency of
ATP similar between CD73
+/+ mice and CD73
2/2 mice, the
potency was similar to the potency of adenosine, as shown here
and as previously reported [1–3]. Previous studies have reported
that the inhibitory effects of ATP are mediated by adenosine
acting at A1 receptors, as they are blocked by A1 receptor
antagonists and are not evident in adenosine A1 receptor
2/2 mice
[1]. ATP analogues such as ATPcS, b,c-imido-ATP, and b,c-
methylene-ATP have similar potency for inhibiting fEPSPs as
adenosine and ATP [1,2,5]. As the effects of these analogues are
inhibited by adenosine deaminase and DPCPX, and potentiated
by the nucleoside transport inhibitor dipyridamole, it was
concluded that these ATP analogues require metabolism to
adenosine and activation of A1 receptors for their effects [1,2].
The availability of CD73
2/2 mice allowed a new approach to
evaluate the role of CD73 in regulating adenosine levels. However,
instead of establishing the importance of CD73 for the inhibitory
effects of ATP, our results support the opposite conclusion.
In the present study, DPCPX increased synaptic activity by
blocking A1 receptor activity mediated by basal adenosine levels.
DPCPX was effective in both preventing (Fig. 5) and blocking
(Fig. 4) the inhibitory effects of ATP, as has been reported
previously using theophylline [3] or 8-cyclopentyltheophylline [1].
NBTI, which decreased synaptic transmission by reducing cellular
uptake of adenosine and enhancing basal adenosine levels, added
to the inhibitory effect produced by ATP. AOPCP had no effect
on synaptic transmission, indicating that CD73 was not involved
in regulating basal adenosine levels. Attenuation of the effects of
AMP by AOPCP has been reported previously by some [6] but
not by others [3]. The effects of DPCPX, NBTI and AOPCP were
similar in CD73
+/+ and CD73
2/2 slices, indicating that CD73 is
not required for basal adenosine formation or adenosine formation
from exogenous ATP.
Both hypoxia and oxygen-glucose deprivation decrease synaptic
transmission, which is, in part, mediated by adenosine acting at A1
receptors [22,23]. It has been reported that this adenosine is
formed extracellularly, subsequent to release of ATP from glia
[24]. However, from the data presented here, CD73 is not a key
enzyme required for extracellular adenosine formation during
these conditions.
One explanation for these data is that an enzyme other than
CD73 is responsible for the very rapid generation of adenosine
from released or exogenous ATP. TNAP is an enzyme that
metabolizes extracellular ATP and reduces ATP-dependent
inhibition of axonal growth in cultured neurons [14]. We
examined the effect of TNAP-I, reported to inhibit TNAP with
an inhibitory constant (Ki) of 600 nM [15]. Interestingly, the
inhibitory effects of AMP were significantly reduced by TNAP-I,
but only in slices from CD73
2/2 mice. Furthermore, synaptic
inhibition produced by oxygen-glucose deprivation was attenuat-
ed, but only in slices from CD73
2/2 mice. These data indicate
that TNAP is a significant contributor to adenosine production
when CD73 is absent. From quantitative PCR of cDNA samples,
we found similar expression of TNAP in CD73
+/+ and CD73
2/2
brain samples, yet formation of [
14C]adenosine from [
14C]AMP
was significantly inhibited by TNAP-I in CD73
2/2 but not
CD73
+/+ samples. Therefore, in the absence of CD73, TNAP had
a measurable effect on adenosine production, but this was not
evident in samples that contain CD73, likely because the abundant
CD73 activity masked the small contribution of TNAP. TNAP-I is
a selective inhibitor of TNAP [15] and TNAP expression was
similar in CD73
+/+ and CD73
2/2 mice; however, it remains
possible that adaptive changes occurred as a result of the loss of
Figure 8. TNAP-I reduces oxygen-glucose deprivation (OGD)-
induced decreases in fEPSP recordings from CD73
2/2 mice.
Slices were superfused with TNAP-I as indicated by the horizontal bar
and were superfused with (a) hypoxic aCSF for 10 min or (b) hypoxic
glucose-free aCSF for 3 min as indicated by the second horizontal bar.
n=6 CD73
+/+ or 7 CD73
2/2 mice (a) or from n=5 CD73
+/+ or 8 CD73
2/2
mice (b). Significant differences between genotypes are indicated by
dashed lines. p,0.05; unpaired t-tests.
doi:10.1371/journal.pone.0039772.g008
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2/2 tissues and these may underlie the different
effects of TNAP-I between the two genotypes.
The results reported here are in contrast to our previous
findings with cultured rat cortical neurons, astrocytes and co-
cultures of neurons and astrocytes [18,25] in which we found that
astrocytes and co-cultures, but not neuron cultures, produced
extracellular adenosine via a mechanism that was inhibited by
AOPCP. Similarly, several studies report that CD73 is important
for regulating adenosine levels in peripheral tissues during hypoxia
and inflammation [11,13,26]. These studies led us to propose that
ATP, released as a gliotransmitter, was an important source of
adenosine during basal conditions, hypoxia/ischemia and treat-
ment with the ionotropic glutamate receptor agonist N-methyl-D-
aspartate. It has previously been reported that the gliotransmitter
ATP is important for adenosine production during basal
conditions and theta burst stimulation used to produce long term
potentiation, but not during hypoxic conditions [27,28]. It has also
been reported that adenosine is released directly and not produced
from extracellular ATP [29–32]. Thus, while several lines of
investigation indicate that cellular release of ATP and CD73
activity are important for producing extracellular adenosine, other
mechanisms for adenosine regulation are also evident. From the
studies reported here, we conclude that CD73 is not a key enzyme
for regulating extracellular adenosine levels, or adenosine A1
receptor activity, in basal or hypoxic/ischemic conditions in
hippocampal slices during low frequency stimulation.
Previously, we reported that neuronal ENTs are more
important for adenosine uptake than adenosine release during
low frequency stimulation of normoxic, hypoxic or ischemic
hippocampal slices [9]. Interestingly, a recent report [32]
concluded that ENTs were responsible for adenosine release from
hippocampal CA1 neurons during high frequency stimulation.
These experiments used intraneuronal delivery of inosine to
competitively inhibit ENT-mediated adenosine release and
attenuate the inhibitory effect of adenosine at its receptors.
Further research is required to reconcile these contrasting findings.
In conclusion, this study shows that CD73 is active in brain of
Wt mice but the absence of CD73 does not reduce the activation
of adenosine receptors that occurs in response to exogenous
application of ATP or in response to hypoxia or OGD. TNAP
activity was only evident when CD73 was absent and does not
appear to provide a significant contribution to adenosine
production in Wt mice. Whether another enzyme, perhaps
restricted to the membrane microdomains containing adenosine
A1 receptors, contributes to adenosine production in physiological
and pathological conditions remains to be determined.
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